125 related articles for article (PubMed ID: 10708857)
1. HIV protease as a target for retrovirus vector-mediated gene therapy.
Todd S; Anderson C; Jolly DJ; Craik CS
Biochim Biophys Acta; 2000 Mar; 1477(1-2):168-88. PubMed ID: 10708857
[TBL] [Abstract][Full Text] [Related]
2. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
3. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
Todd MJ; Luque I; Velázquez-Campoy A; Freire E
Biochemistry; 2000 Oct; 39(39):11876-83. PubMed ID: 11009599
[TBL] [Abstract][Full Text] [Related]
4. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Sayer JM; Louis JM
Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
[TBL] [Abstract][Full Text] [Related]
5. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Stoffler D; Sanner MF; Morris GM; Olson AJ; Goodsell DS
Proteins; 2002 Jul; 48(1):63-74. PubMed ID: 12012338
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
7. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
8. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
Gaucher B; Rouquayrol M; Roche D; Greiner J; Aubertin AM; Vierling P
Org Biomol Chem; 2004 Feb; 2(3):345-57. PubMed ID: 14747863
[TBL] [Abstract][Full Text] [Related]
9. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
[TBL] [Abstract][Full Text] [Related]
10. Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Tomasselli AG; Heinrikson RL
Biochim Biophys Acta; 2000 Mar; 1477(1-2):189-214. PubMed ID: 10708858
[TBL] [Abstract][Full Text] [Related]
11. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
[TBL] [Abstract][Full Text] [Related]
12. Oximinoarylsulfonamides as potent HIV protease inhibitors.
Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques.
Okafor SN; Angsantikul P; Ahmed H
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293006
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
Wlodawer A; Vondrasek J
Annu Rev Biophys Biomol Struct; 1998; 27():249-84. PubMed ID: 9646869
[TBL] [Abstract][Full Text] [Related]
17. Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.
Braz AS; Tufanetto P; Perahia D; Scott LP
Proteins; 2012 Dec; 80(12):2680-91. PubMed ID: 22821809
[TBL] [Abstract][Full Text] [Related]
18. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.
Rouquayrol M; Gaucher B; Greiner J; Aubertin AM; Vierling P; Guedj R
Carbohydr Res; 2001 Nov; 336(3):161-80. PubMed ID: 11705466
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Hong L; Zhang XC; Hartsuck JA; Tang J
Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]